Cover
Vol. 3 No. 1 (2025)

Published: June 1, 2025

Pages: 13-32

Original Article

The Evolution of Drug Delivery Systems: Historical Advances and Future Directions

Hassanian Sagban Taghi 1 Maher Abdulrazzaq Al-hakeem 2 Yasir Qasim Almajidi 1
1Department of Pharmacutics, College of pharmacy, Al-Bayan University, Baghdad, Iraq
2Department of Pharmacutics, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
History
  • Received: March 5, 2025
  • Accepted: March 29, 2025
  • Available Online: June 1, 2025

Abstract

Drug delivery methods have evolved to improve therapeutic outcomes, patient compliance, and therapy outcomes. This review examines the historical progression of drug delivery strategies, current innovations, and emerging trends shaping the future of therapeutic approaches. Traditional methods of giving medications, like oral and injection routes, had many problems, such as low bioavailability and systemic side effects. This review looks at how drug delivery systems have changed throughout several drug development eras. It focuses on new developments such as nanotechnology-based delivery, biologics, and the creation of smart drug delivery systems. This review highlights breakthroughs in controlled-release systems, nanocarriers, transdermal patches, and implantable drug-delivery devices, comparing both conventional and modern strategies. Further, advances in microencapsulation technology, gene therapy delivery strategies, and AI-assisted drug formulation are examined in the context of precision and efficacy. These innovations reflect a paradigm shift toward precision medicine with personalized drug delivery strategies minimizing side effects while maximizing therapeutic outcomes. Importantly, nanomedicine and biological therapies have successfully addressed critical challenges of drug stability, bioavailability, and drug delivery mechanisms for controlled release devices

Keywords

References

  1. Peterson K. Competing by saving lives: How pharmaceutical and medical device companies create shared value in global health. FSG; 2012.
  2. Nixdorff K, Davison N, Millett P. Technology and biological weapons: Future threats. 2004.
  3. Dave VS, Gupta D, Yu M, Nguyen P, Varghese Gupta S. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules. Drug Dev Ind Pharm. 2017;43(2):177-89.
  4. Montano MF, Mehdi H, Nash DB. Annotated bibliography: understanding ambulatory care practices in the context of patient safety and quality improvement. Am J Med Qual. 2016;31(2_suppl):29S-43S.
  5. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. 2023;23(1):689.
  6. Tottoli EM, Dorati R, Genta I, Chiesa E, Pisani S, Conti B. Skin wound healing process and new emerging technologies for skin wound care and regeneration. 2020;12(8):735.
  7. Metrangolo V, Engelholm LH. Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers. 2024;16(2):447.
  8. Zhao X-F, Wang M-C, Huang J-C, Qiang Y, Yoon I-S. Nanomaterials and nanodevices. The Scientific World Journal. 2015;2015.
  9. Roth DJ, Cuatrecasas P. The distributed partnering model for drug discovery and development. 2010.
  10. Zhang X, Chu Z, Ren L, Xing J. Open innovation and sustainable competitive advantage: The role of organizational learning. Technol Forecast Soc Change. 2023;186:122114.
  11. Sheth RA, Sabir S, Krishnamurthy S, Avery RK, Zhang YS, Khademhosseini A, et al. Endovascular embolization by transcatheter delivery of particles: past, present, and future. 2017;8(2):12.
  12. Waldman SA, Terzic A. Process improvement for maximized therapeutic innovation outcome. Clin Pharmacol Ther. 2018. p. 8-12.
  13. Zhao X-F, Wang M-C, Huang J-C, Qiang Y, Yoon I-S. Nanomaterials and nanodevices. The Scientific World Journal. 2015;2015:250401.
  14. Alex M, Alsawaftah NM, Husseini GA. State-of-all-the-art and prospective hydrogel-based transdermal drug delivery systems. Appl Sci. 2024;14(7):2926.
  15. Tiwari H, Rai N, Singh S, Gupta P, Verma A, Singh AK, et al. Recent advances in nanomaterials-based targeted drug delivery for preclinical cancer diagnosis and therapeutics. 2023;10(7):760.
  16. Bordbar-Khiabani A, Gasik M. Smart hydrogels for advanced drug delivery systems. Int J Mol Sci. 2022;23(7):3665.
  17. Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102.
  18. Boniolo F, Dorigatti E, Ohnmacht A, Saur D, Schubert B, Menden MP. Artificial intelligence in early drug discovery enables precision medicine. Expert Opin Drug Discov. 2021;16(9):991-1007.
  19. Ullah I. CRISPR/Cas9-Based Genome Editing in Precision Medicine: Current Trends and Recent Advancements. Genes. 2024;1:100001.
  20. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database (Oxford). 2020;2020:baaa010.
  21. Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP, et al. The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 2021;9:628137.
  22. Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, et al. Towards the sustainable discovery and development of new antibiotics. 2021;5(10):726-49.
  23. Stejskalova A, Kiani MT, Almquist BD. Programmable biomaterials for dynamic and responsive drug delivery. Exp Biol Med. 2016;241(10):1127-37.
  24. Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, et al. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment. 2024;9(1):34.
  25. Kaur CD, Mishra KK, Sahu A, Panik R, Kashyap P, Mishra SP, et al. Theranostics: New era in nuclear medicine and radiopharmaceuticals. In: Medical Isotopes. IntechOpen London, UK; 2020.
  26. Zahid AA, Chakraborty A, Shamiya Y, Ravi SP, Paul A. Leveraging the advancements in functional biomaterials and scaffold fabrication technologies for chronic wound healing applications. Mater Horiz. 2022;9(7):1850-65.
  27. Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. 2023;8(1):418.
  28. Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules. 2023;28(18):6624.
  29. Tawbi H, Nimmagadda N. Targeted therapy in melanoma. Biologics. 2009:475-84.
  30. Waldman SA, Terzic A. Clinical Pharmacology & Therapeutics: past, present, and future. Clin Pharmacol Ther. 2017. p. 300-3.
  31. Oliver R, Tillotson J, Toomey A. Bioengineered Textiles and Nonwovens–the convergence of bio-miniaturization and electroactive conductive polymers for assistive healthcare, portable power, and design-led wearable technology. J Fibre Bioeng Inform. 2009;2(1):1-13.
  32. Bussooa A, Neale S, Mercer JR. Future of smart cardiovascular implants. Sensors. 2018;18(7):2008.
  33. Borgogna M, Bellich B, Cesàro A. Marine polysaccharides in microencapsulation and application to aquaculture: “from sea to sea”. Mar Drugs. 2011;9(12):2572-604.
  34. Perán M, García MA, López-Ruiz E, Bustamante M, Jiménez G, Madeddu R, et al. Functionalized nanostructures with application in regenerative medicine. 2012;13(3):3847-86.
  35. Padalkar AN, Shahi SR, Thube MJ. Microparticles: an approach for the betterment of drug delivery system. Int J Pharm Res Dev. 2011;3(1):99-115.
  36. Savas Jr PE. Therapeutic Delivery Technology and its Economic Impact. 2019.
  37. Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, et al. A One Health overview, facilitating advances in comparative medicine and translational research. 2016;5:1-7.
  38. Srivastav AK, Karpathak S, Rai MK, Kumar D, Misra DP, Agarwal V, et al. Lipid-based drug delivery systems for oral, transdermal and parenteral delivery: Recent strategies for targeted delivery consistent with different clinical application. J Drug Deliv Sci Technol. 2023;85:104526.
  39. Bidram M, Zhao Y, Shebardina NG, Baldin AV, Bazhin AV, Ganjalikhany MR, et al. mRNA-based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients. 2021;9(10):1060.
  40. Singh P, Muhammad IJ, Nelson NE, Tran KT, Vinikoor T, Chorsi MT, et al. Transdermal delivery for gene therapy. 2022;12(11):2613-33.
  41. Danaeifar M. Recent advances in gene therapy: genetic bullets to the root of the problem. Clin Exp Med. 2023;23(4):1107-21.
  42. Riahi R, Tamayol A, Shaegh SAM, Ghaemmaghami AM, Dokmeci MR, Khademhosseini A. Microfluidics for advanced drug delivery systems. Curr Opin Chem Eng. 2015;7:101-12.
  43. Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K. Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis. Cancers. 2019;11(7):906.
  44. Zargar A, Chang S, Kothari A, Snijders AM, Mao J-H, Wang J, et al. Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy. 2019;5(4):258-66.
  45. Correia A, Monteiro A, Silva R, Moreira J, Lobo JS, Silva A. Lipid nanoparticle strategies to modify the pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders. Adv Drug Deliv Rev. 2022;189:114485.
  46. Nikandish M, Wang H, Bao X, Nikandish M. Advancements in Nanoparticle-Based Precision Drug Delivery: A Review of Development and Optimization for Targeted Therapy in Preclinical Models. European Scientific Journal. 2024;20(27):49.
  47. Kumar R, Igwegbe CA, Khandel SK. Nanotherapeutic and Nano-Bio Interface for Regeneration and Healing. Biomimetics. 2024;12(12):2927.
  48. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomimetics. 2022;10(9):2055.
  49. Sultana S, Alzahrani N, Alzahrani R, Alshamrani W, Aloufi W, Ali A, et al. Stability issues and approaches to stabilized nanoparticles based drug delivery system. 2020;28(5):468-86.
  50. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306.
  51. Truong-Le V, Lovalenti PM, Abdul-Fattah AM. Stabilization challenges and formulation strategies associated with oral biologic drug delivery systems. Adv Drug Deliv Rev. 2015;93:95-108.
  52. Omogbadegun Z, Ayo C. Impact of mobile and wireless technology on healthcare delivery services. 2007;24(8):163.
  53. Manipriyanka K, Naidu RK. Advances in Drug Formulation Technology: Enhancing Bioavailability and Patient Compliance. J Pharm Sci. 2023;44.
  54. Gagliardi D, Ramlogan R, Navarra P, Russo CD. Diffusion of complementary evolving pharmaceutical innovations: The case of Abacavir and its pharmacogenetic companion diagnostic in Italy. Technol Forecast Soc Change. 2018;134:223-33.
  55. Mittra J, Tait J, Wield D. From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries. Trends Biotechnol. 2011;29(3):105-9.
  56. Ginsburg PB. High and rising health care costs: Demystifying US health care spending. Synthesis Project, Robert Wood Johnson Foundation; 2008.
  57. Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature. 2015;526(7573):361-70.
  58. Bae YH, Park K. Advanced drug delivery 2020 and beyond: Perspectives on the future. Adv Drug Deliv Rev. 2020;158:4-16.
  59. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
  60. Greineder CF, Howard MD, Carnemolla R, Cines DB, Muzykantov VR. Advanced drug delivery systems for antithrombotic agents. Blood. 2013;122(9):1565-75.
  61. Shahiwala A. Advancing drug delivery research: sustainable strategies for innovation and translation. Drug Discov Res. 2025:1-12.
  62. Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. 2019;8(6):3167-81.
  63. Aljabali AA, Tambuwala MM, Obeid MA. Microfluidic manufacturing of niosomes. In: Microfluidics in Pharmaceutical Sciences: Formulation, Drug Delivery, Screening, and Diagnostics. Springer; 2024. p. 77-108.
  64. Strianese O, Rizzo F, Ciccarelli M, Galasso G, D’Agostino Y, Salvati A, et al. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. 2020;11(7):747.
  65. Sharun K, Banu S, Mamachan M, Abualigah L, Pawde AM, Dhama K. Unleashing the future: Exploring the transformative prospects of artificial intelligence in veterinary science. Journal of Experimental Biology and Agricultural Sciences. 2024;12(3):297–317.
  66. Shorna S, Sultana R, Hasan M. Transforming Healthcare Delivery Through Big Data in Hospital Management Systems: A Review of Recent Literature Trends. Am J Artif Intell Mach Learn Data Sci Syst. 2024;1(01):1-18.
  67. Gholap AD, Uddin MJ, Faiyazuddin M, Omri A, Gowri S, Khalid M, et al. Advances in artificial intelligence in drug delivery and development: A comprehensive review. Comput Biol Med. 2024:108702.
  68. Andreadis II, Gioumouxouzis CI, Eleftheriadis GK, Fatouros DG. The advent of a new era in digital healthcare: a role for 3D printing technologies in drug manufacturing? Pharmaceutics. 2022;14(3):609.
  69. Heng W, Solomon S, Gao W. Flexible electronics and devices as human-machine interfaces for medical robotics. Adv Mater. 2022;34(16):2107902.
  70. Yadav A, Rai V, Singh S, Kanojia A. Advancements in Soft Robotic Implants for Long-Term Drug Delivery and Tissue Monitoring. J Rob Auton Syst. 2024;3(4):28-39.
  71. Latif S, Qadir J, Farooq S, Imran MA. How 5G wireless (and concomitant technologies) will revolutionize healthcare? Future Internet. 2017;9(4):93.
  72. Stewart SA, Domínguez-Robles J, Donnelly RF, Larrañeta E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Pharmaceutics. 2018;10(12):1379.
  73. Shah N, Kumari M, Sadhu P, Talele C, Rajput HS, Sapra R. "Nano-Herbal Innovations: Precision In Therapeutic Delivery". J Pharm Sci. 2024;45(1).
  74. Omogbadegun ZO. Development of a framework for collaborative healthcare services delivery. Int J Comput Sci Appl. 2013;30.
  75. Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. 2022;6(7):1961-8.
  76. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. 2022;40(2):127-37.
  77. Haddad TC, He J, O’Sullivan CC, Chen B, Northfield D, Dueck AC, et al. Randomized Phase II trial of capecitabine and lapatinib with or without IMC-A12 (Cituxumumab) in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and chemotherapy: NCCTG N0733 (alliance). 2021;188:477-87.
  78. Choi MH, Wan EYF, Wong ICK, Chan EWY, Chu WM, Tam AR, et al. Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalized with COVID-19: a target trial emulation study. 2024;24(11):1213-24.
  79. Cho H, Jammalamadaka U, Tappa K. Nanogels for pharmaceutical and biomedical applications and their fabrication using 3D printing technologies. Materials. 2018;11(2):302.
  80. Yeung C, Chen S, King B, Lin H, King K, Akhtar F, et al. A 3D-printed microfluidic-enabled hollow microneedle architecture for transdermal drug delivery. 2019;13(6).